Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology · Systemic Mastocytosis

Building Your Care Team and Long-Term Monitoring

At a Glance

Systemic mastocytosis requires a multidisciplinary care team led by a hematologist or oncologist. Long-term management involves regular surveillance of tryptase levels, complete blood counts, and bone density scans to monitor organ health and prevent progression.

Because systemic mastocytosis (SM) is a “multisystem” condition, no single doctor can manage it alone. You are the center of a specialized team of experts, each focusing on a different aspect of your health [1][2].

A comprehensive care team typically includes:

  • Hematologist/Oncologist: Usually the lead specialist. They focus on the bone marrow, track your mast cell burden, and manage targeted or cytoreductive therapies [3][4].
  • Allergist/Immunologist: Focuses on “mediator” symptoms and anaphylaxis prevention. They help you identify triggers and manage your emergency action plan and EpiPen [5][6].
  • Gastroenterologist: Necessary if you experience chronic cramping, diarrhea, or malabsorption. They ensure your digestive tract isn’t being damaged by mast cell infiltration [7][8].
  • Dermatologist: Helpful for managing skin-related symptoms (urticaria pigmentosa) and identifying new skin-based signs of the disease [9][10].

Vetting a Specialist

When meeting a new doctor, it is helpful to assess their experience with this rare condition. You might ask [11][12]:

  1. Are you familiar with the 2022 WHO diagnostic criteria for systemic mastocytosis?
  2. How often do you treat patients with my specific subtype?
  3. Do you use highly sensitive tests like ddPCR to track my mutation load?
  4. Do you participate in any national or international mast cell disease networks?

Long-Term Monitoring: Your Surveillance Schedule

Living with mastocytosis means regular check-ups to ensure the disease remains stable. While schedules vary based on your subtype, standard monitoring includes [13][14]:

  • Tryptase Levels: Usually checked every 6–12 months for indolent cases, or more frequently for advanced forms. A rising level can be an early warning sign of disease progression [15][16].
  • Complete Blood Counts (CBC): Used to monitor your red and white blood cells for any signs of “C-findings” (organ damage) like anemia [16][17].
  • Bone Density (DEXA) Scans: Because mast cells can weaken bone, baseline and follow-up scans are vital to monitor for osteoporosis [18][19].
  • Abdominal Imaging: Periodic ultrasounds or CT scans check for an enlarged liver or spleen (organomegaly) [20][21].

Quality of Life: More Than Just Labs

The “hidden” side of mastocytosis is its impact on your daily energy and mental health. Many patients report significant fatigue, “brain fog,” and chronic bone pain [22][12].

It is also normal to experience scan anxiety (stress leading up to lab results) or emotional exhaustion from managing a chronic, unpredictable condition [23][24]. Validating these feelings is a key part of your care. Don’t hesitate to include a counselor or therapist who specializes in chronic illness on your team; mental well-being is as important as any laboratory marker [23].

By building a strong team, having your emergency documentation (like an ER protocol letter and medical alert card) ready, and staying consistent with your monitoring, you can shift from feeling “managed by” the disease to actively managing your own health and survivorship.

Common questions in this guide

What doctors should be on a systemic mastocytosis care team?
A comprehensive care team usually includes a hematologist or oncologist to manage bone marrow health, an allergist or immunologist for anaphylaxis prevention, a gastroenterologist, and a dermatologist.
How often should my tryptase levels be checked?
For indolent systemic mastocytosis, tryptase levels are typically checked every 6 to 12 months. Patients with advanced forms may need more frequent monitoring to watch for early signs of disease progression.
Why do I need a bone density scan if I have mastocytosis?
Mast cells can weaken your bones, increasing the risk of osteoporosis. Baseline and follow-up DEXA scans are essential to monitor your bone health over time and prevent fractures.
What questions should I ask a new doctor about systemic mastocytosis?
It is helpful to ask if they are familiar with the 2022 WHO diagnostic criteria, how many patients with your subtype they treat, and if they use highly sensitive tests like ddPCR to track your mutation load.
What is an emergency protocol letter for mastocytosis?
An emergency protocol letter is a document provided by your specialist outlining your specific condition, triggers, and treatments. It is used to quickly inform emergency room staff how to safely manage your symptoms during a crisis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with systemic mastocytosis do you currently manage in your practice?
  2. 2.Does your center collaborate with other specialists (Allergists, Gastroenterologists, etc.) to coordinate my care?
  3. 3.What is our plan for monitoring my bone density and organ health over the next 5 to 10 years?
  4. 4.If my tryptase begins to rise, at what threshold would we consider repeating a bone marrow biopsy?
  5. 5.Can you provide me with a 'mastocytosis emergency letter' for me to give to other healthcare providers or ER staff?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.

    Gotlib J, Gerds AT, Abdelmessieh P, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(2 D)).

    PMID: 38862005
  2. 2

    Mastocytosis and related entities: a practical roadmap.

    Beyens M, Elst J, van der Poorten ML, et al.

    Acta clinica Belgica 2023; (78(4)):325-335 doi:10.1080/17843286.2022.2137631.

    PMID: 36259506
  3. 3

    Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.

    Jawhar M, Schwaab J, Horny HP, et al.

    European journal of clinical investigation 2016; (46(5)):392-7 doi:10.1111/eci.12607.

    PMID: 26914980
  4. 4

    FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.

    Kasamon YL, Ko CW, Subramaniam S, et al.

    The oncologist 2018; (23(12)):1511-1519 doi:10.1634/theoncologist.2018-0222.

    PMID: 30115735
  5. 5

    Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.

    Lange M, Hartmann K, Carter MC, et al.

    International journal of molecular sciences 2021; (22(5)) doi:10.3390/ijms22052586.

    PMID: 33806685
  6. 6

    Drugs and Vaccines Hypersensitivity in Children with Mastocytosis.

    Mori F, Crisafulli G, Bianchi A, et al.

    Journal of clinical medicine 2022; (11(11)) doi:10.3390/jcm11113153.

    PMID: 35683540
  7. 7

    Cutaneous mastocytosis: A dermatological perspective.

    Di Raimondo C, Del Duca E, Silvaggio D, et al.

    The Australasian journal of dermatology 2021; (62(1)):e1-e7 doi:10.1111/ajd.13443.

    PMID: 33040350
  8. 8

    Aggressive systemic mastocytosis of the liver with cholangitis.

    Waldburger N, Rupp C, Klinke S, et al.

    Hepatic oncology 2015; (2(4)):343-347 doi:10.2217/hep.15.33.

    PMID: 30191016
  9. 9

    Key Pediatric Dermatologic Conditions: A Clinical Review: Part I.

    Kaufman LC, Paradiso MM, Mosser-Goldfarb JL

    Pediatric annals 2026; (55(1)):e41-e46 doi:10.3928/19382359-20251106-03.

    PMID: 41480868
  10. 10

    [Cutaneous mastocytosis - update and clinical guidelines].

    Bergström A, Rollman O, Emtestam L, et al.

    Lakartidningen 2018; (115()).

    PMID: 30351439
  11. 11

    Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.

    Valent P, Akin C, Gleixner KV, et al.

    International journal of molecular sciences 2019; (20(12)) doi:10.3390/ijms20122976.

    PMID: 31216696
  12. 12

    A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.

    Carter MC, Desai A, Komarow HD, et al.

    The Journal of allergy and clinical immunology 2018; (141(1)):180-188.e3 doi:10.1016/j.jaci.2017.05.036.

    PMID: 28629749
  13. 13

    Review and Updates on Systemic Mastocytosis and Related Entities.

    Li JY, Ryder CB, Zhang H, et al.

    Cancers 2023; (15(23)) doi:10.3390/cancers15235626.

    PMID: 38067330
  14. 14

    Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches.

    Paiva ML, Yumeen S, Saliba E, DiMarco C

    JAAD case reports 2023; (36()):63-66 doi:10.1016/j.jdcr.2023.04.009.

    PMID: 37250010
  15. 15

    [Tryptase: A practical guide for the physician].

    Lobbes H, Reynaud Q, Mainbourg S, et al.

    La Revue de medecine interne 2020; (41(11)):748-755 doi:10.1016/j.revmed.2020.06.006.

    PMID: 32712042
  16. 16

    Increased TIM-3 and galectin-9 serum levels in patients with advanced systemic mastocytosis.

    Konantz M, Williams M, Merkel T, et al.

    The Journal of allergy and clinical immunology 2023; (152(4)):1019-1024 doi:10.1016/j.jaci.2023.07.001.

    PMID: 37423405
  17. 17

    Beyond Midostaurin: Role of Avapritinib in Managing Systemic Mastocytosis.

    Pokima N, Khattar G, Keesari PR, et al.

    Cureus 2024; (16(5)):e60161 doi:10.7759/cureus.60161.

    PMID: 38868249
  18. 18

    Skin and bones: systemic mastocytosis and bone.

    Wang M, Seibel MJ

    Endocrinology, diabetes & metabolism case reports 2023; (2023(2)).

    PMID: 37166908
  19. 19

    Management of skeletal-related events and fracture prevention in systemic mastocytosis.

    Lunn EM, Lacount S, Greene LW, Asadipooya K

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025; doi:10.1007/s00198-025-07726-4.

    PMID: 41263967
  20. 20

    Gastrointestinal Disease in Mastocytosis.

    Hamilton MJ

    Immunology and allergy clinics of North America 2023; (43(4)):711-722 doi:10.1016/j.iac.2023.04.005.

    PMID: 37758408
  21. 21

    Urticaria pigmentosa in monochorionic twins.

    Yavuz GO, Yavuz IH, Bilgili SG, et al.

    Indian journal of dermatology, venereology and leprology 2019; (85(5)):509-511 doi:10.4103/ijdvl.IJDVL_163_18.

    PMID: 31389368
  22. 22

    Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey.

    Mesa RA, Sullivan EM, Dubinski D, et al.

    Cancer 2022; (128(20)):3691-3699 doi:10.1002/cncr.34420.

    PMID: 35996873
  23. 23

    Health-Related Quality of Life and Influencing Factors in Adults with Nonadvanced Mastocytosis-A Cross-Sectional Study and Qualitative Approach.

    Pulfer S, Ziehfreund S, Gebhard J, et al.

    The journal of allergy and clinical immunology. In practice 2021; (9(8)):3166-3175.e2 doi:10.1016/j.jaip.2021.04.059.

    PMID: 33965596
  24. 24

    Epidemiology of mastocytosis: a population-based study (Sweden).

    Bergström A, Hägglund H, Berglund A, et al.

    Acta oncologica (Stockholm, Sweden) 2024; (63()):44-50 doi:10.2340/1651-226X.2024.31406.

    PMID: 38380845

This page provides general information about building a systemic mastocytosis care team. Always consult your hematologist or primary care doctor for personalized medical advice and monitoring schedules.

Get notified when new evidence is published on Mastocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.